for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catabasis Pharmaceuticals Inc

CATB.OQ

Latest Trade

2.65USD

Change

0.00(0.00%)

Volume

9,140

Today's Range

--

 - 

--

52 Week Range

1.25

 - 

8.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.65
Open
0.00
Volume
9,140
3M AVG Volume
111.40
Today's High
--
Today's Low
--
52 Week High
8.59
52 Week Low
1.25
Shares Out (MIL)
20.08
Market Cap (MIL)
55.23
Forward P/E
-1.36
Dividend (Yield %)
--

Latest Developments

更多

Catabasis Pharmaceuticals Says Board Approved Reduction In Company’S Workforce Of About 48%- SEC Filing

Catabasis Pharmaceuticals Reports Q3 2020 Results

Catabasis Pharmaceuticals Announces Top-Line Results For The Phase 3 PolarisDMD Trial Of Edasalonexent In Duchenne Muscular Dystrophy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Industry

Biotechnology & Drugs

Contact Info

100 High Street, 28th Floor

BOSTON, MA

02110

United States

+1.617.3491971

http://www.catabasis.com/

Executive Leadership

Kenneth M. Bate

Independent Chairman of the Board

Jill C. Milne

President, Chief Executive Officer, Co-Founder, Director

Noah Clauser

Chief Financial Officer

Benjamin Scott Harshbarger

Senior Vice President, General Counsel

Andrew John Nichols

Chief Scientific Officer

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-12.600

2018

-5.120

2019

-2.350

2020(E)

-2.015
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-79.26
Return on Equity (TTM)
-69.39

Latest News

Latest News

BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data

* CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT

BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent

* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22

* CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC AS OF MARCH 22 - SEC FILING

BRIEF-Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24

* CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING Source text : (http://bit.ly/2CDqdMi) Further company coverage:

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up